BeiGene Initiates New Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab Combined with Chemotherapy as First-line Treatment for Patients with Advanced Squamous Non-Small Cell Lung Cancer in China
BEIJING, China and CAMBRIDGE, Mass., Aug. 9, 2018 /PRNewswire/ -- BeiGene, Ltd.
2018-08-09 17:05
1333